Despite Adverse Events, Roche's Avastin Approved To Enter Chinese Market
This article was originally published in PharmAsia News
Executive Summary
Roche Shanghai announced Sept. 25 that its cancer drug Avastin (bevacizumab) has been approved to enter the general Chinese market